BioRem Balance Sheet Health
Financial Health criteria checks 5/6
BioRem has a total shareholder equity of CA$10.0M and total debt of CA$2.6M, which brings its debt-to-equity ratio to 25.8%. Its total assets and total liabilities are CA$24.4M and CA$14.4M respectively. BioRem's EBIT is CA$7.1M making its interest coverage ratio 29.9. It has cash and short-term investments of CA$7.3M.
Key information
25.8%
Debt to equity ratio
CA$2.57m
Debt
| Interest coverage ratio | 29.9x |
| Cash | CA$7.27m |
| Equity | CA$9.96m |
| Total liabilities | CA$14.42m |
| Total assets | CA$24.38m |
Recent financial health updates
BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet
Jan 25
Is BioRem (CVE:BRM) Using Too Much Debt?
Aug 26Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly
Mar 23BioRem (CVE:BRM) Could Easily Take On More Debt
Aug 25These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well
May 20Recent updates
Investors Continue Waiting On Sidelines For BioRem Inc. (CVE:BRM)
Oct 11Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)
Apr 19BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs Reward
Apr 12BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet
Jan 25Is BioRem (CVE:BRM) Using Too Much Debt?
Aug 26Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly
Mar 23BioRem (CVE:BRM) Could Easily Take On More Debt
Aug 25These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well
May 20Here's What's Concerning About BIOREM's (CVE:BRM) Returns On Capital
Jan 26Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay Cheque
Nov 23
Financial Position Analysis
Short Term Liabilities: BRM's short term assets (CA$21.9M) exceed its short term liabilities (CA$11.4M).
Long Term Liabilities: BRM's short term assets (CA$21.9M) exceed its long term liabilities (CA$3.0M).
Debt to Equity History and Analysis
Debt Level: BRM has more cash than its total debt.
Reducing Debt: BRM's debt to equity ratio has increased from 0% to 25.8% over the past 5 years.
Debt Coverage: BRM's debt is well covered by operating cash flow (210.8%).
Interest Coverage: BRM's interest payments on its debt are well covered by EBIT (29.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioRem Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|